Definitive Healthcare Corp. Stock Price, News & Analysis

Definitive Healthcare (Nasdaq: DH) has expanded its Population Intelligence platform to serve a wider range of industries selling into healthcare. The platform now supports businesses in sectors like advertising, marketing, telehealth, staffing, and medical supply to enhance marketing campaigns and digital advertising performance.

Population Intelligence combines clinical and consumer data on over 250 million unique consumers aged 18+, offering 300+ clinical propensity, social determinants of health, and media channel models. This allows businesses to create precise audience segments and launch targeted marketing campaigns, driving efficient consumer activation.

The platform enables teams to segment markets, build campaign audiences, and activate audiences for digital advertising. It integrates with organizations' internal systems while keeping first-party data secure, promoting compliance with data privacy standards.

Definitive Healthcare Corp. (Nasdaq: DH) reported financial results for Q2 2024. Revenue grew 5% year-over-year to $63.7 million. The company incurred a net loss of $306.2 million, primarily due to goodwill impairment charges of $363.6 million. However, Adjusted EBITDA increased 21% to $20.9 million, representing 33% of revenue.

Key highlights include:

• Adjusted Net Income: $14.2 million
• Cash Flow from Operations: $14.0 million
• Unlevered Free Cash Flow: $21.5 million
• Enterprise customers grew by 32 (6% YoY) to 537

For Q3 2024, DH expects revenue between $61.0-$62.5 million and Adjusted EBITDA of $17.5-$19.0 million. Full-year 2024 guidance projects revenue of $247-$251 million and Adjusted EBITDA of $74-$77 million.

Definitive Healthcare Corp. (Nasdaq: DH), a leader in healthcare commercial intelligence, has announced the timing for its second quarter 2024 financial results conference call and webcast. The company will report its financial results for the quarter ended June 30, 2024, on Monday, August 5, 2024, after market close.

A conference call and webcast will be held at 5:00 PM (ET) / 2:00 PM (PT) to discuss the results. Investors can access the live audio webcast on the company's Investor Relations website. A live dial-in will also be available. Following the call, a replay will be accessible through September 4, 2024.

Definitive Healthcare (Nasdaq: DH) has launched a redesigned mobile app for its View Suite platform, aimed at enhancing accessibility to healthcare commercial intelligence. Announced on July 09, 2024, the new DH View Suite mobile app provides sales and marketing teams with instant access to essential data, optimizing their productivity in the field. The app offers detailed profiles of healthcare professionals and organizations, including metrics on clinical performance, finances, and more. Available for download on Apple and Android devices at no additional cost to existing customers, the app ensures that users are always prepared for client meetings and industry events.

On June 25, 2024, Definitive Healthcare (Nasdaq: DH) announced the granting of inducement awards to its new CEO, Kevin Coop. The awards include 1,137,038 performance-based restricted stock units (PSUs) and 1,170,047 time-based restricted stock units (RSUs), effective June 24, 2024. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4) and are a part of the company's 2023 Inducement Plan.

The RSUs will vest in stages, with one-fourth vesting on July 1, 2025, and the rest in 12 equal quarterly installments. The PSUs are divided into four tranches, tied to specific stock price hurdles and performance periods, with vesting subject to the Human Capital Management and Compensation Committee's certification and Mr. Coop's continued service.

Definitive Healthcare (Nasdaq: DH) has been awarded the 2024 Databricks Healthcare and Life Sciences Partner of the Year. This accolade highlights their successful collaboration with Databricks in offering innovative data and AI solutions to the healthcare and life sciences sector.

Leveraging the Databricks Marketplace, Definitive Healthcare provides access to extensive datasets, including prescription claims, behavioral health data, and affiliations intelligence. This aids organizations in understanding patient journeys, prioritizing opportunities, and engaging key medical experts for better healthcare outcomes.

Casey Eastlack, AVP at Definitive Healthcare, expressed pride in the recognition, emphasizing the shared mission to deliver deeper and faster healthcare insights for improved decision-making and innovation. Michael Sanky of Databricks praised the partnership's impact on advancing outcomes for customers in the sector.

Definitive Healthcare (Nasdaq: DH) published its 2023 Sustainability Report, showcasing its achievements in environmental, social, and governance (ESG) practices. Highlights include the retention of an ESG consultant to measure greenhouse gas emissions, and the closure of its least energy-efficient office. On the social front, the company improved diversity at the executive level, contributed 1,940 volunteer hours, and raised over $300,000 in charitable donations. In governance, Definitive Healthcare completed a SOC2 assessment and enhanced its cybersecurity and data privacy framework.

Definitive Healthcare, a leader in healthcare commercial intelligence, announced that Founder, Interim CEO, and Executive Chairman, Jason Krantz, will present at the Stifel 2024 Cross Sector Insight Conference. The presentation is scheduled for June 4, 2024, at 9:10 a.m. ET. A live webcast will be available on the Definitive Healthcare investor relations website, with a replay accessible for a time. The announcement highlights the company's active role in industry events and its ongoing efforts to engage with investors and stakeholders.

Definitive Healthcare (Nasdaq: DH) announced the appointment of Kevin Coop as CEO, effective June 24, 2024. Coop replaces Jason Krantz, who served as Interim CEO and will remain as Executive Chairman. Coop brings over 30 years of experience in operations, product, and revenue growth, including leadership roles at DailyPay, Dun & Bradstreet, Black Knight, and Verisk Analytics. The company aims to leverage Coop's expertise to capitalize on the $10 billion healthcare commercial intelligence market, enhancing growth, innovation, and operational efficiency.